ReproCell Inc (4978.T)

4978.T on Tokyo Stock Exchange

22 Mar 2018
Change (% chg)

¥6 (+1.79%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

ReproCELL plans JV with Q Therapeutics Inc
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - ReproCELL Inc <4978.T> ::Says it reaches agreement to set up a joint venture with US-based firm Q Therapeutics Inc, which is mainly engaged in development of regenerative medicine products.New JV will be mainly engaged in joint research on iPS cells regenerative medicine products for patient with diseases of the central nervous system .  Full Article

ReproCell announces exercise of options
Thursday, 25 May 2017 

May 25(Reuters) - ReproCell Inc <4978.T>:Says 600 of its 12th series options were exercised to 600,000 shares as of May 25.  Full Article

ReproCell says exercise of warrants
Tuesday, 14 Feb 2017 

ReproCell Inc <4978.T>:Says 630 of its 12th series warrants were exercised into 630,000 shares, during the period from Feb. 1 to Feb. 14.  Full Article

ReproCell announces merger among 3 subsidiaries
Monday, 1 Aug 2016 

ReproCell Inc <4978.T>: Says its 71.6 percent owned subsidiary, Bioserve Biotehnologies, Ltd., will merge with two other wholly owned subsidiaries, Stemgent Inc. and Biopta Inc. . Says after the transaction, Bioserve Biotehnologies, Ltd. will be the surviving company, Stemgent Inc. and Biopta Inc. will be dissolved . Bioserve Biotehnologies, Ltd. will change company name into ReproCELL U.S.A. Inc., and ReproCell will hold 92.55 percent stake in ReproCELL U.S.A. .Effective date Sep. 1.  Full Article

ReproCell announces merger between two UK-based units
Monday, 6 Jun 2016 

ReproCell Inc <4978.T>: Says a UK-based unit Biopta Ltd., which is engaged in the drug-discovery support services, will undertake a merger with another UK-based unit Reinnervate Ltd on July 1 .Says both of the units are wholly owned by the company and the unit's name will be changed into ReproCELL Europe Ltd. after the merger.  Full Article

ReproCell appoints Daitsuke Utsui as CFO
Friday, 13 May 2016 

ReproCell <4978.T>:Says it appoints Daitsuke Utsui as CFO, effective June 24.  Full Article

ReproCELL lowers consolidated full-year outlook for FY 2016
Monday, 2 May 2016 

ReproCELL Inc:Says the company lowered the consolidated full-year outlook for the FY ended March 2016.Revenue forecast decreased to 1,066 million yen from 1,530 million yen.Operating profit forecast decreased to a loss of 1,023 million yen from a loss of 555 million yen.Ordinary profit forecast decreased to a loss of 1,168 million yen from a loss of 495 million yen.Net profit forecast decreased to a loss of 1,960 million yen from a loss of 495 million yen.Earnings per share decreased to a loss of 36.13 yen from a loss of 9.53 yen.Comments that decreased sales and impact of expense and exchange rate are the main reasons for the forecast.  Full Article

BRIEF-ReproCell to set up JV with Fox Chase

* Says it will set up a JV, BIOSERVE BIOREPOSITORY, LCC, with Fox Chase, Ltd